Market News & Trends
Vividion Therapeutics Announces Strategic Research Collaboration With Celgene; $101 Million Up-Front Payment
Vividion Therapeutics, Inc., a biotechnology company using revolutionary proteomics and chemistry platforms, recently announced a strategic research collaboration with Celgene Corporation. The multi-year collaboration is focused…
Aduro Announces Development Milestone Achieved Under Merck Collaboration
Aduro Biotech, Inc. recently announced that the company earned a $3-million development milestone payment under its worldwide licensing agreement with Merck (known as MSD outside…
Catalent Completes Multi-Million Expansion at Singapore Clinical Supply Facility
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the completion…
ProJect Pharmaceutics Expands Facilities for Formulation & Lyophilization Process Development
ProJect Pharmaceutics (PJP), specialized in formulation and process development for parenteral drug products, announces that it has extended its safety facilities by laboratories dedicated to…
Fierce Competition Amongst Checkpoint Inhibitor Developers Ahead
Over the next ten years, PD-(L)1 inhibitors will continue to dominate the checkpoint modulators market, says leading data and analytics company GlobalData. PD-(L)1 inhibitors are…
Colorcon Makes Tablets Easier to Swallow
Dysphagia is a common ailment often experienced by the geriatric population. Opadry EZ, Easy Swallow Film Coating System, a new innovative product from Colorcon Inc,…
Soleno Therapeutics Announces Successful End-of-Phase II Meeting With FDA
Soleno Therapeutics, Inc. recently announced the successful completion of and receipt of minutes from its End-of-Phase 2 Meeting with the US FDA concerning Diazoxide Choline…
Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors
Fate Therapeutics, Inc. recently announced the first subject has been treated in the DIMENSION study of FATE-NK100 for the treatment of advanced solid tumors. The…
Bioluminescent Imaging Capabilities Accelerate Robust CAR T-Cell Therapy
Crown Bioscience recently announced it has enhanced its existing platform for chimeric antigen receptor (CAR) T-cell agent evaluation with bioluminescent imaging capabilities. CAR T-cell therapies…
Sernova’s Clinical Trial Supported With Continuous Glucose Monitoring Systems
Sernova Corp. recently announced continuous glucose monitoring systems [CGM (Medtronic Minimed, Northridge, CA)] will be provided to patients in Sernova’s US regenerative medicine clinical trial…
Amunix Announces Licensing Agreement With Celgene
Amunix Operating Inc. recently announced it has entered into a licensing agreement with Celgene. The agreement allows for the utilization of Amunix’s proprietary XTEN and…
Novo Nordisk Successfully Completes Phase 3a Trial Using Emisphere's Technology
Novo Nordisk recently announced the successful completion of the first Phase 3a trial, PIONEER 1, with oral semaglutide, a once-daily oral formulation of the long-acting…
Biohaven Announces Exclusive License Agreement With Catalent
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") recently announced it has entered into an exclusive worldwide license agreement with Catalent U.K.…
Lonza Expands Encapsulation & HPAPI Capabilities in North America
Lonza recently announced the expansion of its late-stage clinical and commercial encapsulation capabilities for solid oral and inhaled dosage forms in North America. The company…
Shire Provides Regulatory Progress Update for Key Pipeline Programs Targeting Rare Disease
Shire plc recently announced the US FDA has granted Orphan Drug Designation to Shire's investigational therapy, SHP647, for the treatment of pediatric patients with moderately…
Regentys, Cook Biotech to Collaborate in Developing, Delivering Unique Ulcerative Colitis Treatment
Regentys recently announced it will partner with Cook Biotech Inc. to develop a novel treatment for ulcerative colitis. Under the terms of a signed letter…
Malvern Panalytical Launches New Morphologi 4 Range for Fast, High-Definition Particle Characterization Throughout Drug Development
The new Morphologi range of automated static imaging systems for particle characterization from Malvern Panalytical – Morphologi 4 and Morphologi 4-ID – has been unveiled.…
Horizon Discovery Enters License Agreement With US Immuno-Oncology Company
Horizon Discovery Group plc recently announced it has entered into a non-exclusive out-licensing agreement with a US-based immuno-oncology therapeutics developer (the Partner) for Horizon’s proprietary…
CordenPharma Announces Revamped Executive Leadership Team
CordenPharma is pleased to announce the appointments of Dr. Riku Heikki Rautsola as the new Chief Executive Officer & President, CordenPharma, Dr. Walter Kittl as…
Verona Pharma Provides Clinical Development Update
Verona Pharma plc recently announced updated projections, bringing forward the timing for top-line data readouts from its ongoing clinical trials in chronic obstructive pulmonary disease…
